2.435
2.21%
-0.055
Cellectis ADR stock is currently priced at $2.435, with a 24-hour trading volume of 216.95K.
It has seen a -2.21% decreased in the last 24 hours and a -5.25% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.52 pivot point. If it approaches the $2.38 support level, significant changes may occur.
Previous Close:
$2.49
Open:
$2.4895
24h Volume:
216.95K
Market Cap:
$179.68M
Revenue:
$16.50M
Net Income/Loss:
$-85.02M
P/E Ratio:
-1.2236
EPS:
-1.99
Net Cash Flow:
$-66.74M
1W Performance:
-4.51%
1M Performance:
-5.25%
6M Performance:
+142.29%
1Y Performance:
+27.49%
Cellectis ADR Stock (CLLS) Company Profile
Name
Cellectis ADR
Sector
Industry
Phone
33 1 81 69 16 00
Address
8, rue de la Croix Jarry, Paris
Cellectis ADR Stock (CLLS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-17-23 | Initiated | Bryan Garnier | Buy |
May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
May-12-20 | Initiated | Robert W. Baird | Outperform |
Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
Oct-30-19 | Resumed | Guggenheim | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
May-24-19 | Resumed | Citigroup | Neutral |
Mar-14-19 | Initiated | William Blair | Outperform |
Dec-19-18 | Initiated | Goldman | Neutral |
Jul-16-18 | Initiated | Barclays | Overweight |
Mar-16-18 | Initiated | Guggenheim | Neutral |
Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
Sep-05-17 | Reiterated | Wells Fargo | Outperform |
Mar-02-17 | Initiated | Instinet | Buy |
Feb-28-17 | Initiated | Wells Fargo | Outperform |
Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
Jul-20-15 | Initiated | BofA/Merrill | Buy |
Apr-20-15 | Initiated | Jefferies | Buy |
Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis ADR Stock (CLLS) Latest News
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
GlobeNewswire Inc.
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
GlobeNewswire Inc.
Cellectis présentera deux posters sur un nouveau procédé d’édition par TALEN® pour la correction et l’insertion de gènes dans les cellules souches et progénitrices hématopoïétiques (HSPCs) à l’ASGCT
GlobeNewswire Inc.
CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
GlobeNewswire Inc.
Monthly information on share capital and company voting rights
GlobeNewswire Inc.
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
GlobeNewswire Inc.
Cellectis ADR Stock (CLLS) Financials Data
Cellectis ADR (CLLS) Revenue 2024
CLLS reported a revenue (TTM) of $16.50 million for the quarter ending September 30, 2023, a +242.29% rise year-over-year.
Cellectis ADR (CLLS) Net Income 2024
CLLS net income (TTM) was -$85.02 million for the quarter ending September 30, 2023, a +18.50% increase year-over-year.
Cellectis ADR (CLLS) Cash Flow 2024
CLLS recorded a free cash flow (TTM) of -$66.74 million for the quarter ending September 30, 2023, a +38.72% increase year-over-year.
Cellectis ADR (CLLS) Earnings per Share 2024
CLLS earnings per share (TTM) was -$1.67 for the quarter ending September 30, 2023, a +38.15% growth year-over-year.
About Cellectis ADR
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cap:
|
Volume (24h):